Japan
Korea
China
Mr. Crouse has served as our Chief Executive Officer and as a Board Director since July 2017. From December 2015 to July 2017, Mr. Crouse was a consultant for private equity sourcing and leading a proprietary process to acquire CBR in partnership with GTCR. Prior, Mr. Crouse served as Chief Executive Officer of Cord Blood Registry (CBR) from September 2012 to August 2015 when it was sold to AMAG Pharmaceuticals for $700M. He served as Executive Vice President of AMAG until December 2015. From April 2011 through September 2012, Mr. Crouse was a consultant for private equity evaluating sourcing and leading a proprietary process to acquire CBR in partnership with GTCR. Mr. Crouse previously served as Chief Operating Officer at Immucor, Inc. from 2009 to 2011, which was purchased by TPG Capital in a public-to-private transaction for $2B. Before Immucor, he served as Vice President of the life sciences business at Millipore Corporation. Prior to joining Millipore, he worked at Roche where he held various roles in NA and Europe. Mr. Crouse served on the Board of Directors of Invitae Corporation from 2012 to 2024. Mr. Crouse also served on the Board of Generate Life Sciences after supporting the acquisitions and combination of CBR and CalCryo by GI partners from 2018 until 2021 when the Company was sold to Cooper Surgical for $1.6B. Mr. Crouse holds a B.A. in English from Boston College and an M.B.A. and Master of Public Health from the University of California Berkeley.
Mr. Bailey has served as our Chief Financial Officer since August 2024. Mr. Bailey is responsible for leading the Company’s global financial organization and initiatives which include data and analytics, business planning and forecasting, accounting and financial reporting, internal audit and risk management and tax and treasury. Mr. Bailey also leads our information technology strategy and organization together with the Company’s Chief Information Officer. Mr. Bailey has served in the position of CFO or CEO for over 20 years. Prior to joining Candela, Mr. Bailey served as CFO at NanoString Technologies, AgaMatrix Holdings LLC, and at Angiotech Pharmaceuticals where he also served for two years as CEO. Prior to his operating roles, Mr. Bailey worked for over a decade as an investment banker, including in the life sciences practice group at Credit Suisse and Donaldson Lufkin & Jenrette. During his time in investment banking, he advised on over 50 completed transactions including mergers, acquisitions, strategic alliances and a range of equity, equity linked and debt financing. Mr. Bailey has also served as a member of the Board of Directors and Audit Committee Chair for IZI Medical Holdings, AgaMatrix Holdings, Angiotech Pharmaceuticals, Lifecare Management Services and OncoGenex Pharmaceuticals. Mr. Bailey received his B.A. in Economics in 1990 from Harvard University and an M.B.A. in 1995 from Harvard Business School.
Ms. Trout joined the Company in July 2017 and has served as our Chief Commercial Officer since November 2018. Ms. Trout is responsible for global product strategy, clinical & regulatory affairs, research and development functions. Ms. Trout also leads global Direct and Distributor business strategy and execution to drive market share and customer lifetime value including the sales, training, post-sales, service, commercial and customer operations functions. Prior to July 2017, Ms. Trout served as Senior Vice President of Maternal Health, and from August 2015 to March 2017 served as Vice President of Maternal Health for AMAG Pharmaceuticals Inc. Ms. Trout served as Vice President of Field Operations, Cord Blood Registry from 2013 to 2015 when it was sold to AMAG Pharmaceuticals. From 2008 to 2013, Ms. Trout led the Immucor, Inc. strategic partnerships organization and served as Director of Corporate Accounts from June 2010 to May 2013. Ms. Trout served as board member for Vyaire, Inc from 2019 to 2024. Ms. Trout holds a B.S. in Biological Sciences from the University of Nebraska and an M.B.A. from California Pacific University.
Mr. Moulle-Berteaux has served as Chief Marketing Officer since July 2025. Mr. Moulle-Berteaux is responsible for developing, leading, and managing Candela’s global marketing strategies to accelerate revenue growth and customer lifetime value. This includes the optimization of Customer Acquisition Cost to Customer Lifetime Value with the aim of increasing our profitability and accelerating growth. Mr. Moulle -Berteaux has over 25 years of experience launching new products, scaling customer engagement and driving revenue growth in technology, media, and telecommunications industries. Mr. Moulle-Berteaux was co-founder and Chief Executive Officer for Starry, Inc., a next generation wireless technology developer and internet service provider that scaled to five cities and was the fastest growing residential internet service provider for several years. Mr. Moulle-Berteaux also served as Chief Operating Officer for five years. Prior to Starry, Inc, Mr. Moulle-Berteaux served as Chief Marketing Officer at Aereo and Rockstar Games (TTWO); and managed worldwide marketing campaigns across all Apple products for a number of years as the Global Head of Brand Leadership at TBWA (OMNICOM). He earned a bachelor’s degree in philosophy from Boston College.
Ms. Soderquist has served as Chief Human Resources Officer since February 2017. Ms. Soderquist is responsible for leading the Company’s human resources organization which includes the planning, and implementation of human resources strategies – policies, programs, and services, guiding the organizational culture, management of compensation, benefits, and equity programs learning solutions, talent and performance management, and internal communications. Before Candela, Ms. Soderquist served as VP, Talent Management and Human Resources for Allergan plc where she co-steered the company’s integration of its people strategy following the sale to Actavis plc for US$70.5B in 2014. Ms. Soderquist has held global human resources positions of increasing responsibility with the Roche Group, KLA-Tencor Inc., SupportSoft GMBH, in Canada, Europe, Singapore, and the U.S. Ms. Soderquist earned a B.S. in Business Administration from the University of Massachusetts, Amherst, and an Advanced Degree in European Economics from the University of Copenhagen.
Mr. Davidson has served as SVP, Global Operations since January 2021. He is responsible for leading global Manufacturing, Supply Chain, and Technical Transfer which includes strategic planning and execution, S&OP, global logistics, manufacturing, and procurement. Prior, Mr. Davidson was Head of Global Supply Chain at Ortho Clinical Diagnostics and was accountable for world-wide Sales & Operations Planning, Inventory Planning & Management, Warehouse Operations, Distribution, Import/Export Management & Compliance, Supply Chain systems, Ex Ops and Material Master Data. Before Candela, Mr. Davidson served as the Head of Divisional Development, EMD Millipore (Nasdaq: MRK) from 2012 until 2014. Prior, Mr. Davidson was the Vice President, Finance Global Operations, Roche Diagnostics, The Roche Group from 2010 to 2012. Mr. Davidson earned a B.S., Business from Indiana University.
Ms. Fronio joined the Company in August 2023 and now serves as Group SVP, Product Strategy and Innovation. Ms. Fronio is responsible for leading Candela’s product innovation strategy, lifecycle management and implementation end to end which includes the Global Business Units (GBU) – portfolio strategy and ongoing product management, and Global Innovation - Research, Product Development & Engineering, Quality, Regulatory, Clinical Affairs and Global Service Operations. Specifically, execution on product roadmap priorities, portfolio financial analysis and reporting, advancing enterprise projects leveraging data to deliver customer value and developing an accelerated growth strategy for improving recurring revenue and expanding gross margins. Prior to joining Candela, Ms. Fronio successfully served organizations such as Vyaire Medical, Acelity/KCI, Allergan/Lifecell, J&J / Ethicon in progressive leadership roles. Ms. Fronio holds a B.A., Allied Health Sciences with a concentration in Cytotechnology, and an M.B.A. with a concentration in Marketing from the University of Connecticut.
Mr. Ross joined the Company May 2025 as our SVP & CIO, Global IT Strategy and Operations. Mr. Ross is responsible for developing and executing Candela’s information technology vision to ensure it aligns with the company’s strategic objectives. He will lead the planning and implementation of forward-thinking IT initiatives—ranging from enhancing device connectivity and developing customer-facing software (including firmware), optimizing data management, and driving digital transformation across product demonstration, ordering, and transaction systems. In addition, elevating Candela’s customer experience, boost operational efficiency, and enable scalable growth through technology. Prior, Mr. Ross was Chief Information Officer at NanoString Technologies and Bruker Spatial Biology where he led data architecture and system management for highly multiplexed spatial profiling. Prior to that, he served as Chief Information Officer for NeoGenomics Laboratories and Vice-President Technology for Chicos, leading all ecommerce solutions. Mr. Ross holds a Bachelor of Science, Engineering Technology, from New Mexico State University.
Mr. Blood has served as Chief Legal Officer and General Counsel since January 2018. He is responsible for shaping and leading the Company’s global legal function which includes M&A, licensing, commercial, trade and contractual matters, intellectual property, healthcare and medical device compliance privacy, antitrust, corporate governance, and international law. Mr. Blood joined us from Voyager Therapeutics, a public biotechnology company focused on neurological gene therapies, where he served as Vice President of Legal Affairs. Prior to Voyager Therapeutics, Mr. Blood served as Vice President of Legal Affairs, Deputy General Counsel and Chief Compliance Officer at Amag Pharmaceuticals, a public pharmaceutical and medical device company. Prior to Amag Pharmaceuticals, Mr. Blood held various roles of increasing responsibility at EMD Serono, the U.S. pharmaceutical division of Merck KGaA and worked at the law firms Goodwin Procter in Boston and Montgomery McCracken in Philadelphia. Mr. Blood earned his J.D. from Northeastern University School of Law and a B.S. in International Relations from Georgetown University.